MedCity News July 21, 2019
Alaric DeArment

While well-developed in cancers, precision medicine’s readiness for prime time beyond oncology varies markedly from disease to disease. But reimbursement remains a significant hurdle.

More than a decade ago, the science fiction author William Gibson said, “The future is here – it’s just not evenly distributed.” It’s impossible to know exactly what went through his mind when he said that, but the statement could just as easily be applied to the field of precision medicine.

Much of the focus on precision medicine – which involves taking into account individual patients’ genetics, environment and lifestyle – has focused on cancers, especially with the rise of next-generation sequencing (NGS) and drugs that target specific biomarkers.

Today's Sponsors

LEK
ZeOmega

Today's Sponsor

LEK

Continue Reading

 
Topics: Biotechnology, Physician, Precision Medicine, Provider, Technology
Related Articles:
Exploring the potential of personalized precision medicine for healthcare industry
Putting Patients First by Extending the Reach of World-Class Care
Healthcare's most promising tech
AI In Healthcare: A New Era Of Personalized Patient Care
23andMe reports sales decline a day after announcing plans to cut 40% of workforce

Share This Article